Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Folitixorin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTHFD2 | P13995 | 2/20 | 0.70 |
| ▸ | MTHFD1 | P11586 | 2/20 | 0.70 |
| ▸ | DHFR | P00374 | 2/20 | 0.58 |
| ▸ | MTR | Q99707 | 1/20 | 0.57 |
| ▸ | GART | P22102 | 6/20 | 0.54 |
| ▸ | SOST | Q9BQB4 | 1/20 | 0.54 |
| ▸ | ATIC | P31939 | 4/20 | 0.54 |
| ▸ | TYMS | P04818 | 1/20 | 0.52 |
| ▸ | FPGS | Q05932 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arfolitixorin SCHEMBL29551275 | 1.00 | MTHFD2 (0.70) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL9430909 | 1.00 | MTHFD2 (0.70) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL3180668 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL16467076 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL50782 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL4108452 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL186747 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL258730 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Arfolitixorin SCHEMBL29616436 | 0.97 | MTHFD2 (0.74) | MTHFD2MTHFD1DHFRMTRGART | |
| Folitixorin SCHEMBL4537420 | 0.96 | MTHFD2 (0.73) | MTHFD2MTHFD1DHFRMTRGART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5300505-A | Stable salts of 5,10-methylenetetrahydrofolic acid | EPROVA AKTIENGESELLSCHAFT (CH) | 1994-04-05 | — | — | US | claimed |
| JP-5294968-A | — | — | None | — | — | JP | disclosed |
| US-12103930-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2024-10-01 | — | — | US | disclosed |
| US-20220143027-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2022-05-12 | — | — | US | disclosed |
| US-11306094-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2022-04-19 | — | — | US | disclosed |
| US-20200283443-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2020-09-10 | — | — | US | disclosed |
| US-10570134-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2020-02-25 | — | — | US | disclosed |
| US-20190270745-A1 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2019-09-05 | — | — | US | disclosed |
| US-10336758-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2019-07-02 | — | — | US | disclosed |
| US-10059710-B2 | Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | Merck & Cie (CH) | 2018-08-28 | — | — | US | disclosed |
| US-20160030573-A1 | STABLE PHARMACEUTICAL COMPOSITIONS OF 5,10-METHYLENETETRAHYDROFOLATE | Merck & Cie (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9180128-B2 | Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolate | Merck & Cie (CH) | 2015-11-10 | — | — | US | disclosed |
| CN-1842337-B | Stable 5, 10-methylene tetrahydrofolate pharmaceutical composition | MERCK EPROVA AG | 2010-05-26 | — | — | CN | disclosed |
| US-20070099866-A1 | Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolate | MERCK EPROVA AG (CH) | 2007-05-03 | — | — | US | disclosed |
| CN-1842337-A | Stable 5, 10-methylene tetrahydrofolate pharmaceutical composition | MERCK EPROVA AG (CH) | 2006-10-04 | — | — | CN | disclosed |
| US-5455236-A | Stable aqueous compositions | EPROVA AKTIENGESELLSCHAFT (CH) | 1995-10-03 | — | — | US | disclosed |
| EP-0579996-B1 | Inclusion compounds of 5,10-methylenetetrahydrofolic acid and cyclodextrin | EPROVA AG (CH) | 1995-05-03 | — | — | EP | disclosed |
| US-5300505-A | Stable salts of 5,10-methylenetetrahydrofolic acid | EPROVA AKTIENGESELLSCHAFT (CH) | 1994-04-05 | — | — | US | disclosed |
| EP-0579996-A1 | Inclusion compounds of 5,10-methylenetetrahydrofolic acid and cyclodextrin | EPROVA Aktiengesellschaft (CH) | 1994-01-26 | — | — | EP | disclosed |
| JP-H05294968-A | STABLE SALT OF 5,10-METHYLENETERAHYDROFOLIC ACID | EPROVA AG | 1993-11-09 | — | — | JP | disclosed |